Gunning for new targets, new approaches

From CAR-T cells to protein degradation

September 19, 2023

Exploring unexpected targets in brain tumours

As we head into the long August Bank Holiday and Labor Day celebrations, I wanted to offer some…

August 24, 2023

What’s hot in lung cancer?

Preview - Wwat to watch for at WCLC23

July 27, 2023

Making sense of all the TIGIT data at ASCO23

Continuing our coverage of the annual meeting of ASCO in Chicago I felt compelled to review the actual…

June 6, 2023

On TIGIT, ADCs, and other stories

Some ASCO23 abstracts to watch out for and why

May 31, 2023

Tipping the TIGIT balance

How can we overcome immune escape in relation to TIGIT therapies?

January 9, 2023

Chasing the alpha

A deeper look at the ARC-7 TIGIT readout

December 20, 2022

Emerging biotechs and novel IO concepts to watch out for

10 early stage IO biotechs to watch out for

November 30, 2022

SITC Preview 2 – a look at novel and emerging IO targets

Five areas of early stage IO developments to watch out for

October 14, 2022

What do the Konami code and targeting KRAS have in common?

A rock around the KRAS clock

July 12, 2022

The spectre of MetMAB rises again!

Six important factors to consider when looking at the SKYSCRAPER-01 TIGIT readout

May 11, 2022

The paradox of immune cell populations and transcription factors

Can you have your immune cake and eat it?

March 23, 2022

Science drives innovation

A careful look at the latest anti-TIGIT data

January 25, 2022

What to watch out for on the CAR-T cell therapy front

Several controversies abound in the CAR-T cell niche this year, plus what's coming next?

December 7, 2021

Lessons learned from SITC – Part 1

Sometimes we learn more from failure than we do from success

November 16, 2021

Scores on the doors in the TIGIT niche

Update on the various runners and riders in the TIGIT niche

November 3, 2021
Washington DC in Fall

SITC21 – What to Watch out for

SITC 2021 Preview

October 22, 2021

Looking east at a now familiar horizon

A careful look at what we can learn from the Beigene anti-TIGIT data for ociperlimab

July 6, 2021

Tackling immunosuppression with a dual approach to TIGIT and adenosine

Do we need to target the adenosine fog as well as TIGIT in NSCLC?

June 24, 2021

A twist in the IO tail

Going beyond the obvious conclusion with anti-LAG3 therapy

May 19, 2021

Emerging developments and trends in advanced lung cancer

Gems from the WCLC20 poster hall which may make an impact

February 9, 2021

Parallel lines: opportunities and challenges in GI cancers

Important developments on the GI cancer front to watch out for

January 19, 2021

A contrarian view of key cancer trial results

Winners, losers and risers... who goes where in the final analysis?

October 8, 2020
Hubble Space Telescope, Spitzer Space Telescope

On black holes and rising supernova stars in oncology

Rising stars become supernovas or disappear into a black hole of R&D - a look at what we can learn from one company's early stage compounds

October 6, 2020

Can we add fire to the immune system with TIGIT?

A look at Genentech's tiragolumab (anti-TIGIT) in advanced lung cancer

June 1, 2020

Putting some colour on the TIGIT niche

A look at what a young up and coming biotech in the TIGIT space are doing and how they see their approach being differentiated from the competition.

May 12, 2020

Every cloud has a silver lining

What to watch out for at AACR20 - the first of our meeting previews is here!

April 15, 2020

10 early phase ASH19 abstracts with a difference

A look at off Broadway abstracts on early new product development and scientific findings of interest

November 26, 2019

Next generation approaches to immuno-oncology – where next?

What's next in immuno-oncology: what are potential ways to tackle the patients who do not respond to checkpoint immunotherapy?

January 8, 2015